SCHEMBL26211010

SCHEMBL26211010

CN[C@@H](Cc1ccc(Cl)cc1)C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 6/20 0.54
ATM Q13315 2/20 0.46
PYGL P06737 1/20 0.45
POLB P06746 2/20 0.45
ALDH1A1 P00352 2/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NOS3 P29474 3/20 0.44
NOS1 P29475 3/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
FPR2 P25090 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CDK2 P24941 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30574556 0.98 NOS2 (0.53) NOS2ATMPYGLPOLBALDH1A1
SCHEMBL12379272 0.93 NOS2 (0.49) NOS2PYGLPPARGPPARAFPR2
SCHEMBL14304628 0.88 NOS2 (0.55) NOS2ATMPYGLPOLBALDH1A1
SCHEMBL4307638 0.87 EPHX2 (0.52) NOS2POLBALDH1A1PPARGPPARA
SCHEMBL14289418 0.87 EPHX2 (0.52) NOS2POLBALDH1A1PPARGPPARA
SCHEMBL9114981 0.87 ATM (0.46) NOS2ATMPOLBALDH1A1THRB
SCHEMBL9114979 0.87 ATM (0.46) NOS2ATMPOLBALDH1A1THRB
SCHEMBL24445702 0.85 ESR1 (0.61) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL5614087 0.85 ESR1 (0.61) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL5614085 0.85 ESR1 (0.61) ATMALDH1A1THRBCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA NOS2 4360/4885ATM 2618/4885PYGL 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.